In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

The obesity-care market is largely dominated by just two players: Eli Lilly and Novo Nordisk. 10 stocks we like better than ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk (NVO) stock was down on Tuesday, despite a lack of news from the pharmaceutical company. Instead, investors can ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Hims & Hers Health ( NYSE:HIMS) is positioning itself to capitalize on Novo Nordisk’s ( NYSE:NVO) mounting struggles in the ...